Literature DB >> 685727

The effect of propranolol on serum levels of T4, T3 and reverse-T3 in hyperthyroidism.

G Kallner, J G Ljunggren, M Tryselius.   

Abstract

The effect of propranolol (40 mg t.d.s.) on the peripheral levels of T4, T3 and reverse-T3 was studied in 26 patients with hyperthyroidism. The compounds were measured by specific radioimmunoassay techniques. The levels were followed for five weeks and compared with the levels before treatment. The results show that propranolol had no significant effect on the peripheral levels of T4 despite a rapid amelioration of clinical symptoms. A significant reduction of T3 levels was obtained during the first to fourth week of treatment. No significant decrease was obtained after the fourth week. A significant elevation in reverse-T3 levels was obtained during the second to fourth week of treatment. No significant change was obtained either during the first week or after the fourth week. Inconsistent fluctuations in hormone levels, both before and during treatment, could be seen in individual cases. The results suggest that the reduction of clinical symptoms must be caused by an extrathyroidal action of propranolol which does not seem to involve the pituitary gland.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 685727     DOI: 10.1111/j.0954-6820.1978.tb08394.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

1.  A study of long acting propranolol in the early management of hyperthyroidism.

Authors:  G R Jones; J H Lazarus; D Wynford-Thomas
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

2.  Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.

Authors:  O R Nilsson; A Melander; L Tegler
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

3.  Comparison of propranolol and metoprolol in the management of hyperthyroidism.

Authors:  L E Murchison; J How; P D Bewsher
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.